10-K.Info (Beta Test)
Courtesy of Short Sands, LLC
Income Statement Cash Flow Balance Sheet All Statements
2009 2010 2011 2012 2013 2014 2015
2016 2017 2018 2019 2020 2021 2022
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

GILEAD SCIENCES, INC.

Ticker: GILD   Fiscal Year: 2011

Consolidated Statements Of Income

Period Ending Dec 31, 2011 10-K (Filed: Feb 23, 2012)

(In Thousands)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2011Dec 31, 2010Dec 31, 2009
Revenues:
Product sales
$
8,102,359
7,389,9216,469,311
Royalty revenues268,827545,970491,818
Contract and other revenues14,19913,52950,254
Total revenues8,385,3857,949,4207,011,383
 
Costs and expenses:
Cost of goods sold2,124,4101,869,8761,595,558
Research and development1,229,1511,072,930939,918
Selling, general and administrative1,241,9831,044,392946,686
Total costs and expenses4,595,5443,987,1983,482,162
 
Income from operations3,789,8413,962,2223,529,221
 
Interest and other income, net66,58160,28742,397
Interest expense(205,418)(108,961)(69,662)
Income before provision for income taxes3,651,0043,913,5483,501,956
 
Provision for income taxes861,9451,023,799876,364
Net income2,789,0592,889,7492,625,592
 
Net loss attributable to noncontrolling interest14,57811,50810,163
Net income attributable to Gilead2,803,6372,901,2572,635,755
 
Net income per share attributable to Gilead common stockholders - basic3.623.392.91
Shares used in per share calculation - basic774,903856,060904,604
Net income per share attributable to Gilead common stockholders - diluted3.553.322.82
Shares used in per share calculation - diluted790,118873,396934,109
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

GILEAD SCIENCES, INC.

Ticker: GILD   Fiscal Year: 2011

Consolidated Statements Of Cash Flows

Period Ending Dec 31, 2011 10-K (Filed: Feb 23, 2012)

(In Thousands, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2011Dec 31, 2010Dec 31, 2009
Operating activities:
Net income
$
2,789,059
2,889,7492,625,592
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense72,18767,24064,560
Amortization expense230,045198,237148,384
Stock-based compensation expenses192,378200,041180,684
In-process research and development impairment26,630136,0000
Excess tax benefits from stock-based compensation(40,848)(81,620)(80,186)
Tax benefits from employee stock plans37,23182,08688,368
Deferred income taxes64,06112,152(42,013)
Other non-cash transactions47,93110,40864,456
Changes in operating assets and liabilities:
Accounts receivable, net(375,736)(348,875)(356,462)
Inventories(200,793)(161,190)(75,266)
Prepaid expenses and other assets(13,959)(70,466)(65,667)
Accounts payable428,944(4,453)203,641
Income taxes payable110,771(185,733)166,334
Accrued liabilities300,593120,065109,026
Deferred revenues(29,484)(29,728)48,603
Net cash provided by operating activities3,639,0102,833,9133,080,054
 
Investing activities:
Purchases of marketable securities(5,127,790)(5,502,687)(2,614,046)
Proceeds from sales of marketable securities8,649,7523,033,8931,440,509
Proceeds from maturities of marketable securities788,395683,927435,510
Acquisitions, net of cash acquired(588,608)(91,000)(1,247,816)
Capital expenditures and other(131,904)(61,884)(230,057)
Net cash provided by (used in) investing activities3,589,845(1,937,751)(2,215,900)
 
Financing activities:
Proceeds from issuances of senior notes, net of issuance costs4,660,70200
Proceeds from issuances of convertible notes, net of issuance costs02,462,5000
Proceeds from sale of warrants0155,4250
Purchases of convertible note hedges0362,6220
Proceeds from credit facility0500,000400,000
Repayments of credit facility0(500,000)(400,000)
Proceeds from issuances of common stock211,737221,223222,728
Repurchases of common stock(2,383,132)(4,022,593)(998,495)
Extinguishment of long-term debt(649,987)0(305,455)
Repayments of long-term obligations(1,562)(5,786)(5,648)
Excess tax benefits from stock-based compensation40,84881,62080,186
Contributions from (distributions to) noncontrolling interest(115,037)131,523(44,754)
Net cash provided by (used in) financing activities1,763,569(1,338,710)(1,051,438)
 
Effect of exchange rate changes on cash(16,526)77,469940
Net change in cash and cash equivalents8,975,898(365,079)(186,344)
 
Cash and cash equivalents at beginning of period907,8791,272,958
Cash and cash equivalents at end of period9,883,777907,8791,272,958
 
Supplemental disclosure of cash flow information:
Interest paid62,18015,7488,990
Income taxes paid621,0251,129,577746,224
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

GILEAD SCIENCES, INC.

Ticker: GILD   Fiscal Year: 2011

Consolidated Balance Sheets

Period Ending Dec 31, 2011 10-K (Filed: Feb 23, 2012)

(In Thousands, except shares in actual)
 As ofAs of
 Dec 31, 2011Dec 31, 2010
Assets
Cash and cash equivalents
$
9,883,777
907,879
Short-term marketable securities16,4911,190,789
Accounts receivable, net of allowances of $205,990 at December 31, 2011 and $150,942 at December 31, 20101,951,1671,621,966
Inventories1,389,9831,203,809
Deferred tax assets208,155279,339
Prepaid taxes246,444320,424
Prepaid expenses95,92267,632
Other current assets126,846116,244
Total current assets13,918,7855,708,082
 
Property, plant and equipment, net774,406701,235
Noncurrent portion of prepaid royalties174,584203,790
Noncurrent deferred tax assets144,015153,379
Long-term marketable securities63,7043,219,403
Intangible assets2,066,9661,425,592
Other noncurrent assets160,674181,149
Total assets17,303,13411,592,630
 
Liabilities and Stockholders' Equity
Accounts payable1,206,052803,025
Accrued government rebates516,045325,018
Accrued compensation and employee benefits173,316147,632
Income taxes payable40,5831,862
Other accrued liabilities502,557437,893
Deferred revenues74,665103,175
Current portion of convertible senior notes, net and other long-term obligations1,572646,345
Total current liabilities2,514,7902,464,950
 
Long-term deferred revenues31,87032,844
Long-term debt, net7,605,7342,838,573
Long-term income taxes payable135,655107,025
Other long-term obligations147,73627,401
Commitments and contingencies (Note 12)  
Stockholders' equity:
Preferred stock, par value $0.001 per share; 5,000 shares authorized; none outstanding00
Common stock, par value $0.001 per share; 2,800,000 shares authorized; 753,106 and 801,998 shares issued and outstanding at December 31, 2011 and 2010, respectively753802
Additional paid-in capital4,903,1434,648,286
Accumulated other comprehensive income58,20030,911
Retained earnings1,776,7601,183,730
Total Gilead stockholders' equity6,738,8565,863,729
 
Noncontrolling interest128,493258,108
Total stockholders' equity6,867,3496,121,837
 
Total liabilities and stockholders' equity17,303,13411,592,630
 
External Links 
GILEAD SCIENCES, INC. (GILD) Fiscal Year 2011
Statements of 10-K in Excel https://www.sec.gov/.../Financial.xlxs
Complete 10-K in HTML https://www.sec.gov/.../10-K.html
Complete 10-K in XBRL https://www.sec.gov/.../10-K-xbrl.zip